INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

The Journal of Gynecologic Oncology, published by the Korean Society of Gynecology Oncology & Colposcopy, stands as a premier open access platform since 2011, dedicated to advancing the field of gynecologic oncology. With an ISSN of 2005-0380 and an E-ISSN of 2005-0399, this esteemed journal showcases high-quality research that drives innovation in treatment and care for women affected by gynecologic cancers. Based in South Korea, the journal spans an impressive timeline from 2009 to 2024 and holds a distinguished Q1 ranking in both Medicine (Miscellaneous) and Obstetrics and Gynecology, emphasizing its vital contributions to these fields. The journal is recognized for its rigorous peer-review process and is indexed in Scopus, with notable rankings of #35/209 and #128/404 in Obstetrics and Gynecology and Oncology respectively. As a vital resource for researchers, clinicians, and students alike, it aims to disseminate impactful findings that enhance patient care and foster collaboration across international boundaries.

BMC Gastroenterology is a premier open-access journal published by BMC, dedicated to disseminating high-quality research in the field of gastroenterology. Established in 2001 and headquartered in the United Kingdom, this journal aims to enhance the understanding of gastrointestinal disorders through innovative research, reviews, and clinical studies. With an impressive impact factor and ranking within the Q2 category in gastroenterology and miscellaneous medicine for 2023, BMC Gastroenterology plays a critical role in advancing knowledge and practices in the field. The journal's commitment to open access ensures that researchers, professionals, and students worldwide can freely access and share vital findings and insights. Encouraging collaboration and knowledge transfer, BMC Gastroenterology is an essential resource for those dedicated to improving gastrointestinal health and outcomes.

Journal of Gastrointestinal Cancer, published by SPRINGER, stands as a crucial resource in the fields of Gastroenterology and Oncology. With an ISSN of 1941-6628 and E-ISSN of 1941-6636, this journal has been committed to advancing the understanding and treatment of gastrointestinal cancers since its inception in 2007 and is poised to continue until 2024. The journal is recognized in the Q3 quartiles for both Gastroenterology and Oncology as of 2023, reflecting its relevance and contribution to these vital areas of medical research. Despite not being an open-access journal, it offers printed and online subscription options for access, ensuring that valuable research reaches the hands of practitioners, researchers, and students alike. With a focus on disseminating original research, reviews, and case studies, the Journal of Gastrointestinal Cancer plays a pivotal role in fostering ongoing education and discovery in the fight against cancer, promoting better patient outcomes worldwide. The journal is also indexed in Scopus, with notable rankings in the 50th and 45th percentiles for Gastroenterology and Oncology, respectively, further underscoring its scientific merit and credibility in the academic community.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

The Journal of the Turkish-German Gynecological Association, published by GALENOS PUBL HOUSE, stands as a significant contribution to the field of obstetrics and gynecology, fostering a vital dialogue between Turkish and German medical communities since its establishment. This peer-reviewed, Open Access journal, which has been accessible since 2000, provides a platform for the dissemination of cutting-edge research, clinical practices, and reviews that are pivotal for advancing women's health. With a current impact factor correlation reflecting its status within the Q3 category in the obstetrics and gynecology domain, the journal is ranked #108 out of 209 in Scopus, placing it in the 48th percentile for its field. Covering a broad range of topics from innovative treatment methods to emerging technologies in gynecology, this journal is dedicated to enriching the academic landscape and providing healthcare professionals, researchers, and students with valuable insights and knowledge essential for improving patient outcomes. The journal’s headquarters in Turkey underscores its commitment to enriching local and international discourse in women's health.

Minerva Obstetrics and Gynecology, an esteemed journal published by EDIZIONI MINERVA MEDICA, serves as a vital resource in the field of obstetrics and gynecology. With an ISSN of 2724-606X and an E-ISSN of 2724-6450, this open access journal aims to disseminate high-quality research and clinical studies that address contemporary challenges and advancements in women's health. Since its inception in 2021, Minerva Obstetrics and Gynecology has garnered recognition within the academic community, achieving a commendable Q3 ranking in the 2023 category of Obstetrics and Gynecology, and placing at the 54th percentile among peers in its Scopus rankings. The journal not only facilitates the exchange of innovative ideas but also encourages collaboration among researchers, healthcare professionals, and students from around the globe. With a commitment to excellence, it aims to address significant topics that impact clinical practice, ensuring that practitioners remain informed about the latest evidence-based practices. For researchers and practitioners aiming to contribute to the advancement of gynecological and obstetric medicine, Minerva Obstetrics and Gynecology represents a prominent platform for publication and engagement.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.